News

AbstractIntroductionTafamidis is the cornerstone therapy for transthyretin amyloid cardiomyopathy (ATTR–CM); however, validated criteria for monitoring disease…

Investigational PET tracer Iodine 124 Evuzamitide from Bayer meets primary endpoints in Phase III study in patients suspected to have cardiac amyloidosisMay 7…

The oral therapy acoramidis has been approved in Brazil, to be sold as Beyonttra, for treating adults with hereditary or wild-type transthyretin amyloid…

Armed with new phase 3 data, Bayer is preparing to file for approval of a new PET imaging agent that could accelerate the diagnosis of diseases associated with the…

BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by…

AbstractAmyloidosis, characterized by the deposition of abnormal protein fibrils in organs, is classified as systemic or localized. Amyloid light chain (AL)-type…

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen…

BRAZIL - Brazil’s health regulatory agency ANVISA granted marketing authorization for acoramidis, branded as Beyonttra, for treating transthyretin amyloidosis with…

Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this…

Key TakeawaysClaims-based analysis showed 64% of patients received ATTR-CM diagnosis ≥6 months after incident HF, with median delays approaching 1.4 years and…